RENOIR
AnaptysBio’s Rosnilimab Shows Promising Results in Phase 2b Rheumatoid Arthritis Trial, Driving Stock Surge
AnaptysBio, rosnilimab, rheumatoid arthritis, Phase 2b trial, RENOIR study, clinical efficacy, stock price increase, immunology therapeutics